• Fatigue after initiating rivaroxaban for venous thromboembolism 

      Karlsvik, Tina Margrethe; Borgenvik, Thore Langfeldt; Aadalen, Mirjam; Utne, Kristin Kornelia; Førsund, Eli; Jørgensen, Camilla Tøvik; Holst, René; Jelsness-Jørgensen, Lars-Petter; Ghanima, Waleed Khalid (Peer reviewed; Journal article, 2020-03-09)
      Background Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in ...
    • Fatigue after initiating rivaroxaban for venous thromboembolism 

      Karlsvik, Tina Margrethe; Borgenvik, Thore Langfeldt; Aadalen, Mirjam; Utne, Kristin Kornelia; Førsund, Eli; Jørgensen, Camilla Tøvik; Holst, René; Jelsness-Jørgensen, Lars-Petter; Ghanima, Waleed Khalid (Peer reviewed; Journal article, 2020-03-09)
      Background. Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in ...